发现了一种阿基拉小分子TREM2激动剂,具有改善的药理动力学特征和验证的目标参与度
bioRxiv : the preprint server for biology
|July 16, 2025
概括
一个新的分子,C1,作为TREM2激动剂,用于阿尔茨海默病治疗. 与VG-3927相比,它显示出改善的微质功能和药物特性,使其成为有前途的治疗.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
背景情况:
- 在骨髓细胞2 (TREM2) 上表达的触发受体是阿尔茨海默病 (AD) 的关键点,因为它在微质功能中的作用.
- VG-3927是临床开发中的第一个小分子TREM2激动剂,但结构简化可以增强其治疗潜力.
研究的目的:
- 发现和描述C1,一种新型的VG-3927的Achiral结构模拟物,作为一种潜在的TREM2向治疗剂.
- 评估C1在增强微质功能的有效性及其对中枢神经系统透的药理动力学特性.
主要方法:
- 合成C1使用一个模块化,无enantioselective路线与顺序的子合.
- 在HEK293细胞中评估C1的TREM2激活和通过微尺度热泳 (MST) 和表面等离子体共振 (SPR) 的直接结合.
- 评估微质细胞化,代谢稳定性,PAMPA透性和LogD7.4对于中枢神经系统的透.
主要成果:
- C1,VG-3927的立体化学简化的类似物,表现出优异的微质细胞化和TREM2目标参与.
- 证实了C1与TREM2的直接结合,并在相关细胞系中诱导TREM2的激活.
- 与VG-3927相比,C1表现出更好的药物动力学特征,包括增强的代谢稳定性和有利于中枢神经系统透的特性.
结论:
- C1 是一种可合成的,具有药理学优势的TREM2激动剂.
- 这些发现使C1成为开发用于阿尔茨海默病的新型TREM2向治疗的有希望的化合物.
更多相关视频
07:08Efficient Mammalian Cell Expression and Single-step Purification of Extracellular Glycoproteins for Crystallization
Published on: December 23, 2015
13.9K
05:28A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
16.6K
相关概念视频
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
902
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
902
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
663
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
663
